Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban after short-course LMWH versus dalteparin for cancer-associated venous thromboembolism
NL-OMON45054Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of edoxaban and dalteparin in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Primary composite outcome. Started Jul 2015; status: active, not recruiting.
02
Drugs
edoxabandalteparin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NL-OMON45054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45054.